Journal
EPILEPSIA
Volume 58, Issue 3, Pages 315-330Publisher
WILEY
DOI: 10.1111/epi.13621
Keywords
Biomarker; Epileptogenesis; Traumatic brain injury; Imaging; Inflammation; Blood-brain barrier
Categories
Funding
- Neurobiology Commission of the International League Against Epilepsy
- Harinarayan Family Foundation
- Cyberonics Inc. (U.S.A.)
- Insys Therapeutics Inc. (U.S.A.)
- Astellas Pharma (Japan)
- Meiji Seika Pharma (Japan)
- European Union's Seventh Framework Programme (FP7) [602102]
- Dutch Epilepsy Foundation [16-05]
- BOF UAntwerpen
- Research Foundation Flanders (FWO) [1.5.110.14N, G.038515N, G.A009.13N]
- Queen Elisabeth Medical Foundation for Neurosciences
- European Union's Horizon research and innovation programme under the Marie Sklodowska-Curie grant [642881]
- Deutsche Forschungsgemeinschaft [PO681/8-1]
- Academy of Finland
- Canadian Institutes of Health Research [MOP-136839]
- MSD (Japan)
Ask authors/readers for more resources
Neuroimaging offers a wide range of opportunities to obtain information about neuronal activity, brain inflammation, blood-brain barrier alterations, and various molecular alterations during epileptogenesis or for the prediction of pharmacoresponsiveness as well as postoperative outcome. Imaging biomarkers were examined during the XIII Workshop on Neurobiology of Epilepsy (XIII WONOEP) organized in 2015 by the Neurobiology Commission of the International League Against Epilepsy (ILAE). Here we present an extended summary of the discussed issues and provide an overview of the current state of knowledge regarding the biomarker potential of different neuroimaging approaches for epilepsy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
